In this installment of the "How I treat ..." series in Blood , the authors review treatment strategies for T-cell immunophenotype acute lymphoblastic leukemia (T-ALL). The authors note that using pediatric intensive combination chemotherapy regimens in adolescents and young adults has significantly improved the outcome of patients with T-ALL. The authors discuss using allogeneic hematopoietic cell transplantation (HCT) to treat T-ALL, and note that it can be appropriate for patients with high-risk or relapsed/refractory disease. They recommend that older and unfit patients receive upfront multi-agent chemotherapy, with allogeneic HCT as a second-line strategy based on their response, minimal residual disease status, risk factors, and comorbidities.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: Treating T-Cell ALL in Adults
Sep 2015